Molecular analysis of the evolutionary history of endometrial and ovarian carcinoma in Lynch syndrome
International Journal of Cancer · 2025
DOI: 10.1002/ijc.70074 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Anni K Kauppinen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Clinical Genetics, Medicum, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms, Ovarian Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sigrid Juséliuksen Säätiö, University of Helsinki Doctoral Programme in Biomedicine, The Academy of Finland.
Abstract (Originalsprache)
Lynch syndrome (LS) is a prevalent cause of hereditary gynecological cancers. DNA mismatch repair (MMR) defects are important players in LS tumorigenesis, but the developmental steps leading to malignancy are incompletely understood. We undertook a deep sequencing approach with a panel of ~1,000 cancer‐associated genes to detect somatic changes in retrospective specimens from 33 LS carriers who had developed endometrial carcinoma (EC) or ovarian carcinoma (OC). Consecutive samples of atypical endometrial hyperplasia (AH) and EC or OC (64 samples plus blood) were available from a screening period of 15 years (0–15 years). Of carcinomas, all but one (41/42, 98%) were MMR‐deficient by microsatellite instability or immunohistochemical analysis, and 86% (36/42) showed loss of heterozygosity or somatic variants of MMR genes as putative second hits. AH closely resembled EC and OC with respect to MMR deficiency (20/22, 91%) and the presence of second hits (16/22, 73%); moreover, the average tumor mutation burdens and top mutant genes were largely similar in hyperplasia and carcinoma. The proportion of hypermutated tumors (over 10 somatic non‐synonymous mutations per megabase) was 36/42 (86%) among carcinomas and 15/22 (68%) among hyperplasia specimens (statistically non‐significant difference). In individual patients, cancer‐associated genes revealed varying degrees of somatic variant sharing between consecutive specimens of hyperplasia and carcinoma (10/19, 53%), and in some, such variants were detectable in histologically normal endometrium (9/19, 47%) too, one or several years before carcinoma. Our results shed light on the evolutionary trajectories of gynecological cancer development in LS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical and Clinical Genetics, Medicum, University of Helsinki, Helsinki, Finland.
- Department of Education & Research, The Wellbeing Services of Central Finland, Jyväskylä, Finland.
- Department of Sports and Health Sciences, Jyväskylä University, Jyväskylä, Finland.
- HUSLAB Laboratory of Genetics, HUS Diagnostic Center, HUS, Helsinki University Hospital, Helsinki, Finland.
ORCID-Profile: Anni K Kauppinen, Alisa P Olkinuora
Förderung
- Sigrid Juséliuksen Säätiö
- University of Helsinki Doctoral Programme in Biomedicine
- The Academy of Finland
- Syöpäsäätiö
- Biomedicum Helsinki-säätiö
- Jane ja Aatos Erkon Säätiö
Zitieren
APA
Kauppinen, A. K., Olkinuora, A. P., Mecklin, J. P., & Peltomäki, P. T. (2025). Molecular analysis of the evolutionary history of endometrial and ovarian carcinoma in Lynch syndrome. International Journal of Cancer. https://doi.org/10.1002/ijc.70074
Vancouver
Kauppinen AK, Olkinuora AP, Mecklin JP, Peltomäki PT. Molecular analysis of the evolutionary history of endometrial and ovarian carcinoma in Lynch syndrome. International Journal of Cancer. 2025. doi:10.1002/ijc.70074
BibTeX
@article{Kauppinen2025,
author = {Kauppinen, Anni K and Olkinuora, Alisa P and Mecklin, Jukka-Pekka and Peltomäki, Päivi T},
title = {Molecular analysis of the evolutionary history of endometrial and ovarian carcinoma in Lynch syndrome},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.70074}
}
EUVIMED